These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32347069)

  • 1. [Site-specific monoPEGylated interferon alpha2a mediated by microbial transglutaminase].
    Hui X; Cao W; Zhang D; Ge W; Li S; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):750-762. PubMed ID: 32347069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
    Spolaore B; Raboni S; Satwekar AA; Grigoletto A; Mero A; Montagner IM; Rosato A; Pasut G; Fontana A
    Bioconjug Chem; 2016 Nov; 27(11):2695-2706. PubMed ID: 27731976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor.
    Maullu C; Raimondo D; Caboi F; Giorgetti A; Sergi M; Valentini M; Tonon G; Tramontano A
    FEBS J; 2009 Nov; 276(22):6741-50. PubMed ID: 19843182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients.
    Espinosa M; Arenas MD; Aumente MD; Barril G; Buades JM; Aviles B; Carretero D; Alvarez-Lara MA; Carnicer F; Martin-Malo A; Aljama P
    Clin Nephrol; 2007 Jun; 67(6):366-73. PubMed ID: 17598372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.
    Barril G; Quiroga JA; Sanz P; Rodrìguez-Salvanés F; Selgas R; Carreño V
    Aliment Pharmacol Ther; 2004 Jul; 20(1):37-44. PubMed ID: 15225169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical and enzymatic site specific PEGylation of hGH.
    da Silva Freitas D; Mero A; Pasut G
    Bioconjug Chem; 2013 Mar; 24(3):456-63. PubMed ID: 23432141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zwitterlation mitigates protein bioactivity loss
    Han Y; Yuan Z; Zhang P; Jiang S
    Chem Sci; 2018 Dec; 9(45):8561-8566. PubMed ID: 30568780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
    J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
    Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
    Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
    Grace MJ; Lee S; Bradshaw S; Chapman J; Spond J; Cox S; Delorenzo M; Brassard D; Wylie D; Cannon-Carlson S; Cullen C; Indelicato S; Voloch M; Bordens R
    J Biol Chem; 2005 Feb; 280(8):6327-36. PubMed ID: 15596441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-α2a.
    Hauptstein N; Pouyan P; Wittwer K; Cinar G; Scherf-Clavel O; Raschig M; Licha K; Lühmann T; Nischang I; Schubert US; Pfaller CK; Haag R; Meinel L
    J Control Release; 2022 Aug; 348():881-892. PubMed ID: 35764249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
    Ramon J; Saez V; Baez R; Aldana R; Hardy E
    Pharm Res; 2005 Aug; 22(8):1374-86. PubMed ID: 16078148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.